Nevertheless, interest in HER2-low tumors has increased greatly due to the results of the DESTINY-Breast04 trial, which demonstrated the superiority of trastuzumab-deruxtecan (T-DXd) over physician′s choice chemotherapy in patients with advanced HER2-low breast cancer [37]. This evidence concerns the gene ERBB2 and breast cancer.